ArticleBMC anesthesiology2026
Current status of neuromuscular reversal and neuromuscular monitoring in China: a cross-sectional survey.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveResidual neuromuscular blockade (rNMB) is associated with perioperative pulmonary complications. Effective neuromuscular monitoring and the use of reversal agents can help reduce rNMB. We surveyed the current practices of neuromuscular reversal and neuromuscular monitoring among anesthesiologists in China.
methodsWe released a questionnaire containing 25 questions via the New Youth Anesthesia Forum and promoted it through WeChat. We allowed one submission from each IP address. The survey was available online for 30 days. Data were analyzed using descriptive statistics, chi-square tests, and logistic regression analysis.
resultsWe analyzed 3,168 valid questionnaires. Rocuronium (41.76%) and cisatracurium (38.83%) were the most frequently used neuromuscular blocking agents. Only 40.09% of respondents routinely administered pharmacological reversal agents, with neostigmine being the predominant choice (61.11% of total respondents) and sugammadex used by merely 19.03%. The adoption of quantitative neuromuscular monitoring was low, with only 1.61% (n = 51) reported routinely utilizing quantitative monitoring (TOF ratio measurement), while 98.01% relied solely on subjective clinical signs. Logistic regression identified that advanced education (master's or higher) and senior academic rank (associate chief or chief physician) independently predicted greater adoption of neuromuscular monitoring. Anesthesiologists in primary and secondary hospitals demonstrated significantly lower adherence to both antagonist administration and objective monitoring compared to those in tertiary centers.
conclusionsOur findings reveal substantial gaps in adherence to evidence-based practices for managing rNMB in China, particularly concerning the underutilization of quantitative monitoring and sugammadex. Systemic interventions to improve equipment accessibility, drug availability, and targeted education are crucial to enhance patient safety. Policy-driven resource allocation and standardized training programs are recommended to bridge the gap between evidence and practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.